NxStage Medical, Inc. (NASDAQ:NXTM) SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total value of $117,261.00. Following the sale, the senior vice president now owns 28,721 shares in the company, valued at approximately $783,221.67. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

NxStage Medical, Inc. (NXTM) opened at 27.77 on Friday. The stock has a 50 day moving average price of $27.80 and a 200-day moving average price of $25.85. The firm’s market cap is $1.83 billion. NxStage Medical, Inc. has a one year low of $20.45 and a one year high of $30.80.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The company had revenue of $92.20 million for the quarter, compared to analyst estimates of $96.47 million. NxStage Medical had a negative return on equity of 2.43% and a negative net margin of 1.33%. NxStage Medical’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) earnings per share. Analysts predict that NxStage Medical, Inc. will post ($0.05) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/09/24/insider-selling-nxstage-medical-inc-nxtm-svp-sells-117261-00-in-stock.html.

Several analysts have issued reports on NXTM shares. Craig Hallum downgraded NxStage Medical from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Stephens downgraded NxStage Medical from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $33.00 to $30.00 in a report on Wednesday, August 9th. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, June 30th. Jefferies Group LLC downgraded NxStage Medical from a “buy” rating to a “hold” rating and cut their price objective for the stock from $33.00 to $30.00 in a report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded NxStage Medical from a “buy” rating to a “hold” rating in a report on Friday, August 11th. One equities research analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. The stock currently has an average rating of “Hold” and an average target price of $30.25.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Suntrust Banks Inc. raised its position in shares of NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after purchasing an additional 209 shares during the period. Principal Financial Group Inc. raised its position in shares of NxStage Medical by 1.1% during the first quarter. Principal Financial Group Inc. now owns 28,191 shares of the medical device company’s stock worth $757,000 after purchasing an additional 303 shares during the period. Amalgamated Bank raised its position in shares of NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after purchasing an additional 553 shares during the period. Legal & General Group Plc raised its position in shares of NxStage Medical by 3.5% during the second quarter. Legal & General Group Plc now owns 25,349 shares of the medical device company’s stock worth $630,000 after purchasing an additional 856 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of NxStage Medical by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 50,336 shares of the medical device company’s stock worth $1,262,000 after purchasing an additional 1,059 shares during the period. 92.75% of the stock is currently owned by institutional investors.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.